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Abstract: 
Introduction:  
Limited data are available about the ultrasound (US) detected inflammatory features in patients with 
suspicion of inflammatory arthritis (S-IA) vs. established rheumatoid arthritis (RA), in the context of 
no definite clinical synovitis. Our study aimed to investigate several outcome measures, and assess if 
the presence of power Doppler (PD) can be predicted by a combination of clinical, laboratory and US 
parameters. 
Methods:  
We conducted a real-life, retrospective cohort study comparing clinical, laboratory and US parameters 
of 108 patients with established RA and 93 patients with S-IA. Our proposed PD signal prediction 
model was based on a beta-binomial distribution for PD variable using a mix of outcome measures. 
Results: 
Patients with RA in clinical remission had significantly more active inflammation and erosions on US 
when compared with patients with S-IA and similar disease scores (p=0.03 and p=0.01, respectively). 
The PD scores did not correlate with erosions (p=0.38) or DAS-28 scores (p=0.28) in RA patients; 
however, in the S-IA group, DAS-28 scores above 5.1 correlated significantly with the PD score 
(p=0.048). 
Conclusions:  
Subclinical inflammation is more common in patients with RA in clinical remission or with low disease 
activity than in patients with S-IA; therefore US is more useful in assessing for true remission in 
established RA rather than diagnosing IA in patients with low disease activity scores. This is the first 
study to propose a PD prediction model integrating several outcome measures in the two different 
groups of patients. Further research into validating this model can minimise the risk of underdiagnosing 
subclinical inflammation. 
Keywords: joint ultrasound, subclinical inflammation, prediction of power Doppler, rheumatoid 
arthritis, inflammatory joint pains. 
 
INTRODUCTION 
Ultrasound (US) assessment of small joints is routinely used for the diagnosis of peripheral 
inflammatory arthritis (IA) and helps guiding therapeutic decisions in patients with established 
rheumatoid arthritis (RA) (1). The access to musculoskeletal US services varies among hospitals and 
rheumatology services. The usefulness of the US examination for the diagnosis and management of RA 
depends on the level of expertise of examiners and quality of the US machines (2). Even if a 
considerable proportion of patients with established RA continue to have subclinical inflammation, 
despite evidence of clinical remission, it is not cost-effective to screen them all. Extensive US 
examination of peripheral joints in RA had a good predictive value for disease outcome, as established 
by an 18-month longitudinal study (3). As the US examination of multiple joints can be time consuming, 
several US scoring systems have been developed, aiming to assess a smaller number of joints without 
compromising on the quality of data collected (4).   
 
There are no guidelines to help us decide which RA patients should have an US scan of their joints or 
how often, despite the constant effort to generate recommendations regarding the use of imaging 
techniques in the management of patients with RA (5). There is no straightforward indicator of the risk 
of continuing with active joint inflammation, despite the use of several US prediction factors for disease 
progression and damage (6-8).  
The OMERACT (Outcome Measures in RA Clinical Trials) initiative defined the US abnormalities 
characteristic for RA as synovial hypertrophy (SH), with or without Power Doppler (PD) signal, 
tenosynovitis and erosions (4, 9). 
The available US scoring systems use different quantitative or semiquantitative measures (such as 
grades of SH or PD) or a binary scoring system (such as presence/absence of erosions) to express US 
findings (4).  The principal aim of the international and European US expert groups is to develop a 
standardised US scoring system which will capture the patient’s global disease activity and which can 
be employed to guide therapeutic decisions (10).  
As several outcome measures are required to establish if patients with RA have active disease or not, 
we identified the need to integrate clinical and laboratory parameters in a prediction model that could 
improve the quality of care we provide to our patients, by enabling the identification of those at risk of 
having positive PD signal in their joints.  In an ideal situation, patients with a previous diagnosis of RA 
or with the suspicion of having developed IA are offered an US examination of their joints to increase 
the chance of correct diagnosis and optimise disease control. In reality, because of limited resources, 
patients are referred to US clinics in a selective manner, based on their clinician expertise and need, and 
availability of US resources. However, it is widely recognised that subtle joint inflammation is often 
missed by the clinical examination (11). It was proposed that RA treatment should target the control of 
sub-clinical inflammation (as assessed by US or MRI), instead of being exclusively guided by clinical 
examination and laboratory measures (12), and that remission criteria for patients with RA should also 
include joint US examination (13, 14).  
The rationale of our research project was to generate useful information for clinicians that can be easily 
applied in real-life and can help identify patients at risk of having active inflammation in their joints. 
Our statistical modelling framework is based on data routinely collected from a heterogeneous RA 
population.  
The aim of our study was to build a statistical model to assess the influence of several outcome measures 
on the presence of PD signal. The selected outcomes were: the number of tender joints (TJC) and 
swollen joints (SJC) out of 28, global health state as assessed using a visual analogue scale (GVAS), 
high sensitivity C-reactive protein (hsCRP), erythrocyte sedimentation rate (ESR), presence of 
rheumatoid factor (RF) and anti citrullinated cyclic peptides antibodies (ACPA) and anti-nuclear 
antibodies (ANA), disease duration and medication. In order to generate this prediction model, we 
collected similar data from the two groups of patients (with S-IA and RA), and assessed the influence 
of every parameter on the patients’ risk of having active PD in their joints.  
METHODS: 
Subjects 
We conducted a real-life, retrospective cohort study of patients seen to our US outpatient clinics in the 
order of their referral, between May 2013- September 2013. We used an established protocol of US 
examination of hands comprising flexor tendons and 22 joint assessments (dorsal longitudinal and 
transverse views), which is standard of practice for our US clinics. All the patients were referred to this 
clinic for inflammatory symptoms in their hands and their clinical examination was equivocal. No 
inclusion or exclusion criteria were applied for the selection of patients, to ensure the general 
applicability of the prediction model we propose. Patients on oral steroids or NSAIDs, or who had 
steroid injections less than 4 weeks before the US scan were excluded from the final analysis. We report 
data on the two largest groups, the patients with established RA and patients with S-IA, using 
descriptive statistics (SPSS, version 22). We also stratified patients based on their disease activity 
assessed using the DAS-28 score (disease activity score assessing 28 joints). Patient groups with 
different DAS scores were compared using ANOVA/ Chi- Squared test depending on the variables 
analysed (p<0.05 was considered significant). We also performed a cluster analysis of patients with 
similar DAS-28 scores using the aforementioned outcome measures.  
 
Ultrasound examination  
 
US examination was performed using an Logiq S8 US machine (GE Medical Systems Ultrasound and 
Primary Care Diagnostics, Wauwatosa, WI, USA), equipped with a multi-frequency linear matrix array 
transducer (6-15 MHz). B-mode and PD machine setting are optimised and standardised for all our 
patients' US examinations. The settings used were: B-mode frequency 11-15 MHz and Doppler 
frequency 7.5-15 depending on the depth of the anatomical area, Doppler gain around 18 dB, low wall 
filters and pulse repetition frequency 800 Hz. Because of the small number of joints with PD signal 
(only patients with equivocal clinical examination were referred for an US examination of their hands), 
we did not report separately the grades of PD signal.  
 
Statistical analysis for the prediction model 
 
We proposed a regression model to assess the contribution of every outcome measure to the risk of 
having active joint inflammation as well as predict PD signal. We excluded patients with PD signal 
present in more than 10/22 joints to ensure homogeneity in the data. We conducted a real life study 
including 276 patients referred for the suspicion of active joint inflammation (new referrals for S-IA, 
RA patients, and patients with other inflammatory rheumatic conditions). We assessed 22 hand joints 
in every patient, irrespective of their hand symptoms, using the OMERACT scoring system for US 
examination. The proposed regression model was based on a beta-binomial distribution (with the 
response ranging from 0 to 10) for the PD score variable and a mix of main interaction effects for the 
outcome measures stated above. Negative interaction effects show that the respective outcome is 
associated with a lower number of joints with PD signal.  
 
Ethical issues 
The data was collected as standard of practice. The study analysed retrospectively the results of the US 
examinations of patients seen in our US clinics over a defined period of time.  No ethical approval or 
patient’s consent were required as no patient information was used for teaching or new intervention 
research. The results of our study analysis had no impact on the clinical management of patients and 
their confidentiality was maintained. The study was approved by the local Audit Committee (University 
College London NHS Trust, September 2013) and the results communicated as local audit aiming to 
improve the referral criteria to our US clinics (November 2013).    
 
RESULTS 
We collected data from 276 consecutive patients referred to our rheumatologist led US clinic to have a 
scan of their hand joints aiming to answer the clinician question about the presence of active 
inflammation in their joints. There were 108 patients with established RA, 93 were referred for the 
clinical suspicion of IA, 29 were previously diagnosed with psoriatic arthritis (PsA) and 46 patients had 
other diagnoses, including crystal arthropathies, sarcoidosis, osteoarthritis and chronic pain. We 
analysed in parallel the characteristics of the two main groups of patients: the group of established RA 
(n=108) and the group of patients referred with S-IA (n=93) (Table 1).  The assessment of the follow-
up clinical letters of S-IA patients revealed that 50.5% (n=47) were ultimately diagnosed with a form 
of IA, out of which 76.5% (n=36) were diagnosed with RA, 12.7% (n=6) with undifferentiated IA and 
10.6% (n=5) with psoriatic arthritis. The rest of the patients initially referred with the suspicion of IA 
(49.4%) were subsequently diagnosed with non-specific arthralgia, chronic pain or hand osteoarthritis.   
The patients in the RA group were treated with MTX alone or in combination with other synthetic 
DMARDs in 79.6% (86/108), SSZ alone or in combination in 48.1% (52/108) and HCQ alone or in 
combination in 58.3% (58/108). In terms of biologic treatments, 24.07% (26/108) were on etanercept, 
12% (13/108) on adalimumab, 0.018% on certolizumab (2/108), 0.09% on rituximab (10/108), 0.055% 
on tocilizumab (6/108). Out of 108 patients with established RA, 89 patients (82.4%) were on 
combination therapy. The RA patients were on stable conventional and biologic DMARD medication 
for at least one month prior to the scan. A minority of patients (21/108 in the RA group and 9/93 in the 
S-IA group) were treated with additional NSAIDs and one S-IA had oral steroids (Table 1). These 
patients were excluded from the further analysis that stratified them based on their disease activity.  
The comparison between the RA and S-IA groups with regard of the demographic, clinical, laboratory 
and US features are summarised in Table 1. The median number of joints with PD activity was 
significantly higher in RA patients (0, IQR = 2.25 vs. 0, IQR =1, p=0.03), as was the number of joints 
with erosions (p=0.004) and the number of joints with joint effusions (1.5 vs. 0, p=0.013). However the 
percentage of patients having at least one joint with active inflammation, as assessed by the presence of 
PD signal, was not significantly different between the two groups (52/93, 55.9% vs. 45/108, 41.6%, 
p=0.56). Tendon abnormalities (such as effusion and tendon sheet thickening was more frequently 
observed in patients with RA vs. S-IA (14/108 vs. 3/93, p=0.042). The number of clinically assessed 
swollen joints correlated poorly with the US detected inflammation (as assessed by PD signal) in both 
groups of RA and S-IA patients (r=0.27, p=0.54 and r=0.39, p=0.72, respectively).  
The majority of patients with S-IA and positive PD signal in at least one joint (n=52), were subsequently 
diagnosed with a type of inflammatory arthritis (47/52, 90.3%), out of which, 36 patients were 
diagnosed with RA (69.2%). In 5 cases, the presence of PD was associated with osteophytes and they 
have been diagnosed with inflammatory OA. Out of 25.8% of patients with S-IA who had positive RF 
at the time of the US scan (n=24/93), 23 patients were subsequently diagnosed with RA (23/36, 63.3%); 
similarly a proportion of ACPA positive S-IA patients were ulterior diagnosed with RA (18/36, 50%).  
Further analysis compared RA patients stratified based on the DAS-28 activity scores (Table 2) and 
similarly, Table 3 comprises data on the S-IA group (Table 3). As mentioned above, the patients on oral 
steroids and NSAIDs were excluded from this analysis, which reported data on 87 RA and 82 S-IA 
patients. As expected, the RA patients stratified based on their DAS-28 scores had statistically different 
ESR, TJC, SJC, GVAS and pain scores; however they had similar US parameters assessing for active 
and chronic inflammatory changes (Table 2). In contrast, the analysis of patients with S-IA revealed 
that DAS-28 score stratification identified patients with different PD and SH grade 3 scores, CRP and 
ESR levels, as well as patients with different TJC, SJC, GVAS and pain scores (Table 3). In addition, 
the S-IA groups with low, moderate and active disease had a larger proportion of patients with true 
active inflammation (based on PD signal) than the group classified as being in clinical remission 
(p=0.01) (Table 3). The comparison between the patient groups with similar disease activity revealed 
that patients with RA and moderate and high disease activity (DAS-28=3.2-5.1 and >5.1, respectively) 
were significantly different from S-IA patients with similar DAS-28 scores, as far as the disease 
duration, ACPA positivity and number of joints with erosions were concerned (Table 4). RA patients 
in remission (DAS-28<2.6) had significantly higher TJC, number of joints with active inflammation 
and erosions, and higher number of patients with subclinical inflammation, than the S-IA patients 
classified as being in clinical remission (Table 4). We also assessed for correlations between PD signal 
and erosions in RA patients in all the disease activity groups and there were no positive correlations 
(p=0.06, p=0.26, p=0.49, p=0.12 for the different DAS-28 score groups, and p= 0.38 for whole RA 
group, respectively).  Out of all clinical outcomes, only SJC correlated with the PD score, and only in 
patients with RA (p=0.03). The presence of erosions also correlated with the patient’s age and disease 
duration (p=0.04, and p=0.03, respectively).  
Most importantly, the DAS-28 scores did not correlate significantly with the PD scores in the RA 
patients (p=0.25, p=0.87, p=0.13, p=0.22, respectively for the remission, low, moderate and active 
disease respectively). However, in the S-IA group, DAS-28 scores above 5.1 correlated significantly 
with the PD score (p=0.048). 
The binominal model analysis evaluated the impact of several variables on the risk of having active 
joint inflammation assessed by the presence of PD. The most negative values suggested a lower risk for 
positive PD signal in correlation with a certain parameter. Table 5 summarises the marginal effects of 
different variables on the number of joints with PD at the US examination in S-IA, RA patients, and 
patients with other arthropathies (labelled as non S-IA and non-RA). For instance, the average PD scores 
of S-IA patients increased by 0.004856 units in our prediction model as a consequence of having a 
hsCRP level above rather than below 5 mg/l. Similarly, the average PD score of a patient diagnosed 
with RA and treated with tocilizumab decreased by 1.81 units as compared to an RA patient who is not 
treated with tocilizumab (in the context of similar clinical picture and laboratory results). The most 
striking finding was that RA patients treated with tocilizumab tended had a lower PD score on US 
examination than patients treated with other biologics or DMARDs, despite similar clinical and 
laboratory findings (Table 5). The presence of RF increased slightly the risk of positive PD score only 
in patients with S-IA, and ACPA was associated with higher risk of active disease in patients with 
established RA, but had less influence on the S-IA group. Out of all three clinical outcomes, TJC, SJC 
and GVAS, only the SJC correlated with an increased PD score and only in patients with RA. The effect 
of different variables on the risk for a higher PD score was close to a zero value in the case of treatment 
with MTX and etanercept. For example, our prediction model suggested that in this group, the RA 
patients treated with MTX or etanercept monotherapy had a similar risk of having active joint 
inflammation on US. In this particular case, all the outcome measures taken into consideration in the 
prediction model are more relevant than being treated with MTX rather than etanercept. 
We also attempted a cluster analysis of patients with similar DAS-28 scores using the following 
variables: age at scan, duration of symptoms, CRP, ESR, SH grade 1, 2 and 3, PD, presence of 
osteophytes, erosions, TJC, SJC and GVAS. Although, there was no obvious clustering of patients 
based on their diagnosis, the analysis revealed five big clusters with a large jump in the levels of two 
consecutive nodes (Figure 1). One large cluster, including a significant proportion of S-IA patients with 
DAS 28>5.1 exhibited the smallest amount of dissimilarity, suggesting that further analysis of larger 
patient groups might help identify which parameters are best to predict patients’ tendency to cluster in 
a certain disease group.  
Figure 1 represents the dendogram  
 
DISCUSSION 
The results of our comparative analysis between the two groups of patients reflected their selection: 
patients with RA with no obvious clinical signs of active disease, but possible subclinical synovitis, and 
patients with S-IA, who did not fulfil the clinical and laboratory criteria for diagnosis of an 
inflammatory arthropathy and were referred for an US scan. As expected, the number of joints with 
active inflammation and clinical swelling was low. Patient with established RA had longer disease 
duration, and more obvious chronic inflammatory changes (defined as SH and tendon inflammatory 
changes). Chronic joint changes characteristic for RA are known to pose clinical difficulty in assessing 
for the presence of active inflammation. As frequently encountered in clinical practice, patients with 
chronic conditions probably have better coping strategies, and this can account for the reported 
difference in the GVAS assessment between the two groups, despite similar pain scores.   
 
A large proportion of our study patients with positive PD signal in at least one of their hand joints were 
diagnosed with a form of IA following the US scan (91.4%, 43/47), which reiterates the role of US 
examination in the early diagnosis of IA. Also, our study showed that about one in two patients with 
inflammatory joint pains have active arthritis based on US examination, even if they haven’t been 
previously diagnosed with any joint disease.  In addition, the DAS-28 score underestimated the presence 
of active inflammation in 50% patients with RA classified as being in clinical remission; also these RA 
patients had more active disease, more erosions and joint tenderness that subjects with S-IA included 
in the same disease activity group. 
 
The binominal regression analysis model found that certain parameters have can have different impact 
on the PD signal risk prediction. It is difficult to appreciate the magnitude of the effect of different 
parameters taken into consideration in this prediction model because of the limited number of patients 
included in our study. Tocilizumab is considered one of the most potent inhibitors of synovial 
inflammation and was expected to be associated with the lower risk for PD signal, even in the context 
of joint pains. The weak impact of SJC and TJC on the PD presence is a common finding of our 
prediction model and previous US studies.  Our study also emphasised the limited role of the 
inflammatory markers in predicting joint inflammation, as we found that almost half of our RA patients 
with hsCRP below 5 mg/l had at least one joint with positive PD signal. 
 
This is the first study to propose a statistical prediction model integrating clinical, laboratory and US 
parameters aiming to predict which characteristics are associated with an increased risk of having active 
joint inflammation at the US examination in two different groups of patients.  The role of US scans in 
early detection of RA is well established (15), and the probability of developing clinically apparent 
arthritis in the context of positive PD signal was estimated at 94% (16). The main diagnosis difficulties 
arise when a patient does not fulfil criteria for a diagnosis of IA and the availability of US scans is 
limited. Despite the effort to establish guidelines for early diagnosis of RA integrating US data (16), 
there are no algorithms to help with the exclusion of IA in the context of inflammatory hand pains. 
Ideally, all patients with inflammatory hand pain should have an US examination to exclude joint 
inflammation. The US examination was proven effective in altering treatment decision and had 
increased sensitivity compared to clinical examination (17).  
Our real-life observational study confirmed that there were differences between patients with 
established RA and patients referred with suspicion of IA, in terms of parameters associated with the 
presence of PD in their joints and patients’ characteristics. As the patients were referred to have a scan 
because of the difficulty to appreciate if their joints had active inflammation or not, rather than being 
screened for US abnormalities in the context of arthritis, the two groups of patients are not representative 
for the general group of patients with IA and established RA.   
It is interesting to note that the presence of SJ in patients with suspicion of IA did not correlate with the 
presence of PD at the US examination, and that DAS-28 score is not able to discriminate between RA 
patients with more or less active joint inflammation on US.  
It is recognised that patients with established RA have chronic inflammatory changes and the presence 
of swelling is not always indicative of presence of active inflammation, whereas patients with no 
previous diagnosis of arthritis might get swellings if their joints become inflamed. However, previous 
studies found a disparity between the clinical assessment of joint swelling and tenderness and the 
presence of PD signal in patients with established RA (18). In our study, the presence of PD did not 
correlate with the erosion scores in RA patients, probably because the two phenomena are temporarily 
distinct.  Previous studies have been focused on patients with early RA, establishing the importance of 
US for early diagnosis (15), disease progression assessment (19) and prediction of risk to develop 
arthritis (3, 20). The emphasis of our prediction model is rather on finding parameters that suggest the 
need for organising an US examination in certain categories of patients at risk, rather than establishing 
the patients’ risk of developing IA based on prospective serial US examinations, as the majority of 
studies in the literature.  
Our study has some important limitations: the number of patients was too small for enabling definite 
conclusions in relation to the risk prediction model and no practical validation of this model was pursued 
as this was beyond the scope of this study. This prediction risk model, if validated, will ensure patients 
access to US scans based on the stratification of their risk of having sub-clinical joint inflammation to 
minimise the risk of under-diagnosing active RA in the context of limited NHS clinical resources. The 
US score used included only hand joints as the patients referred to our US clinics had hand joint 
inflammatory pains. We do not suggest the extrapolation of our study findings for other joint areas or 
for other inflammatory arthropathies. The distal interphalangeal joints were not examined on purpose, 
as they are not included in the RA OMERACT scores.   
The performance of this prediction model improves with the expansion of the database and also by 
taking into consideration “missing US outcomes”. To address this, we plan to collect data in parallel 
from two RA patient groups (who had and had not a recent US scan) to optimise our model ability to 
predict sub-clinical inflammation in the absence of recorded US outcomes.  A pilot study is also planned 
for the external validation of our risk model, in which we will compare the predicted model outcomes 
with the US data to assess our model performance. 
The authors declared no conflict of interests. 
 Authors contributions: CC designed the project, performed US examinations, collected and analysed  
data, and coordinated and drafted the manuscript, KW and RC participated in the construction of the 
data base, performed part of the statistical analysis and helped to revise the manuscript, MM performed 
US scans, contributed to the collection of data and statistical analysis, JM performed US scans, 
contributed to the collection of data and critical review of the manuscript, GM designed and coordinated 
the statistical analysis, drafted and provided critical review of the manuscript. All authors read and 
approved the final manuscript. 
 
ACKNOWLEDGEMENTS 
CC is funded by Biomedical Research Council fellowship (BRC09/III) 
 
REFERENCES (EndNote) 
 
1. Patil P, Dasgupta B. Role of diagnostic ultrasound in the assessment of musculoskeletal 
diseases. Ther Adv Musculoskelet Dis 2012;4:341-55. 
2. Brulhart L, Ziswiler HR, Tamborrini G, Zufferey P, programmes SS. The importance of 
sonographer experience and machine quality with regards to the role of musculoskeletal ultrasound in 
routine care of rheumatoid arthritis patients. Clin Exp Rheum 2015;33:98-101. 
3. Filer A, de Pablo P, Allen G, Nightingale P, Jordan A, Jobanputra P, et al. Utility of ultrasound 
joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Ann Rheum 
Dis 2011;70:500-7.  
4. Ohrndorf S, Backhaus M. Advances in sonographic scoring of rheumatoid arthritis. Ann Rheum 
Dis 2013;72 Suppl 2:ii69-75. 
5. Mandl P, Naredo E, Wakefield RJ, Conaghan PG, D'Agostino MA, Force OUT. A systematic 
literature review analysis of ultrasound joint count and scoring systems to assess synovitis in rheumatoid 
arthritis according to the OMERACT filter. J Rheumatol 2011;38:2055-62. 
6. Iwamoto T, Ikeda K, Hosokawa J, Yamagata M, Tanaka S, Norimoto A, et al. Prediction of 
relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with 
rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler 
scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res 
2014;66:1576-81. 
7. Pratt AG, Lorenzi AR, Wilson G, Platt PN, Isaacs JD. Predicting persistent inflammatory 
arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required? 
Arthritis Res Ther 2013;15:R118.  
8. Reynolds PP, Heron C, Pilcher J, Kiely PD. Prediction of erosion progression using ultrasound 
in established rheumatoid arthritis: a 2-year follow-up study. Skeletal Rad. 2009;38:473-8.  
9. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, et al. 
Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 
2005;32:2485-7. 
10. Damjanov N, Radunovic G, Prodanovic S, Vukovic V, Milic V, Simic Pasalic K, et al. 
Construct validity and reliability of ultrasound disease activity score in assessing joint inflammation in 
RA: comparison with DAS-28. Rheumatology (Oxford) 2012;51:120-8. 
11. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Wakefield R, et al. Should imaging be a 
component of rheumatoid arthritis remission criteria? A comparison between traditional and modified 
composite remission scores and imaging assessments. Ann Rheum Dis 2011;70:792-8. 
12. Wakefield RJ, D'Agostino MA, Naredo E, Buch MH, Iagnocco A, Terslev L, et al. After treat-
to-target: can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis 2012;71:799-
803. 
13. Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy 
in rheumatoid arthritis? Clin Exp Rheum 2006;24 Suppl 43:S-33-6. 
14. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, et al. Disease remission state in 
patients treated with the combination of tumor necrosis factor blockade and methotrexate or with 
disease-modifying antirheumatic drugs: A clinical and imaging comparative study. Arthritis Rheum 
2009;60:1915-22. 
15. Hazy MD, Slavotinek J, Smith MD. Role of ultrasound in assessment of early rheumatoid 
arthritis. Australasian Rad 2007;51:120-6.  
16. Freeston JE, Wakefield RJ, Conaghan PG, Hensor EM, Stewart SP, Emery P. A diagnostic 
algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound 
when added to conventional assessment tools. Ann Rheum Dis 2010;69:417-9.  
17. Dale J, Purves D, McConnachie A, McInnes I, Porter D. Tightening up? Impact of 
musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated 
using a treat to target strategy. Arthritis Care Res 2014;66:19-26.  
18. Ceponis A, Onishi M, Bluestein HG, Kalunian K, Townsend J, Kavanaugh A. Utility of the 
ultrasound examination of the hand and wrist joints in the management of established rheumatoid 
arthritis. Arthritis Care Res 2014;66:236-44.  
19. Bajaj S, Lopez-Ben R, Oster R, Alarcon GS. Ultrasound detects rapid progression of erosive 
disease in early rheumatoid arthritis: a prospective longitudinal study. Skeletal Rad 2007;36:123-8.  
20. van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR, et al. 
Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated 
arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008;58:2241-7.  
Table 1: Comparison between patients with clinical suspicion of IA and established RA 
Disease S-IA (n=93) RA (n=108) P value 
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Sex (%) 87.1% F (n=81) 79.6% F (n=86) P=0.73 
Duration of the 
symptoms  
6.8 months+/-1.9 
Median: 7 months 
IQR: 13 months 
Median: 60 months 
IQR: 108 
P=0.001 
% (n) of patients on 
NSAIDs and 
painkillers at the time 
of the scan            
 0.096% (9/93)   0.194% (21/108) P=0.023 
% (n) of patients on 
steroids at the time of 
US scan 
0.01 (1/93) 
 
0.05 (6/108) 
 
P = 0.055 
Mean dose 10 mg oral Prednisolone 120 mg DepoMedrone 
i.m (given 5+/-1 week 
ago). 
Number of days since 
given steroids to the 
time of US scan 
One patient on oral 
Prednisolone at the time 
of the scan 
Mean= 19.3+/-15.73 
days 
Median = 19 
IQR = 21.25 
N/A 
hsCRP (mean +/- SE) 
Median and IQR 
6.92 +/- 1.4 5.57+/- 0.76 P= 0.38 
Median: 2.7 IQR: 5.65 Median: 2.9 IQR: 5.95 P= 0.58 
ESR (mean+/- SE) 
Median and IQR 
17.2 +/- 16.3 20.6 +/- 18.8 P= 0.62 
Median: 12 IQR: 18 Median: 14  IQR: 22.75 P= 0.76 
% patients who had 
the blood tests taken 
within 2 weeks from 
the time of the US 
scan 
98% (92/93) 84.4% (92/109) P= 0.009 
% RF positive  25.8% (24/93) 67.6% (73/108) P=0.007 
% ACPA positive  24.7% (22/89) 83% (90/108) P= 0.001 
Number of joints with 
SH gr 1 (median and 
IQR) 
Median: 1.5 
IQR: 2.25 
Median: 2 
IQR: 4.5 
P= 0.54 
Number of joints with 
SH gr 2 (median and 
IQR) 
Median: 0 
IQR: 3 
Median: 1 
IQR: 3 
P= 0.025 
Number of joints with 
SH gr 3 (median and 
IQR) 
Median: 0 
IQR: 0 
Median: 2 
IQR: 4.25 
P=0.013 
Number of joints with 
PD (median and IQR) 
Median: 0 
IQR: 1 
Median: 0 
IQR: 2.25 
P= 0.03 
Number of joints with 
osteophytes (median 
and IQR) 
Median: 1 
IQR: 5.25 
Median: 1 
IQR: 4 
P= 0.23 
Number of joints with 
erosions (median and 
IQR) 
Median: 0 
IQR: 4.5 
Median: 2 
IQR: 8.75 
P= 0.004 
% (n) patients with PD 55.9% (52/93) 41.6% (45/108) P=0.56 
TJC (mean+/- SD) 8.81 +/- 9.07 9.54 +/- 8.9 P=0.57 
Median = 5.5 Median = 6 
SJC (mean+/- SD) 2.66 +/-5.18 
Median = 1 
3.73 +/- 4.74 
Median = 2 
P=0.12  
GVAS (mean+/- SD) 61.7 +/- 25.7 (n=75) 50.7 +/- 28.9 (n=105) P= 0.009 
Pain VAS (mean+/- 
SD) 
59.9 +/-26.6 (n=48) 53.3 +/-31.02 (n=60) P=0.24 
 
 
Table 2: Comparison between RA patients with different levels of disease activity. 
 
Disease 
activity 
RA (n = 11) 
DAS-28<2.6 
 
 
RA (n = 9) 
DAS-28= 
 2.6-3.2 
 
RA (n = 39) 
DAS-28 = 
3.2-5.1 
 
RA (n = 28) 
DAS-28> 5.1 
 
ANOVA/ 
Chi –
squared 
test 
Mean age +/- 
SD 
47.08 +/- 
19.64 
46.33 +/- 
12.59 
58.17 +/- 
16.07 
57.36 +/- 
15.69 
0.051 
Sex (% 
female) 
0.67 0.56 0.65 0.70 0.885 
Duration of 
the symptoms  
7.92  6.71  11.44  8.31  0.300 
hsCRP (mean 
+/- SE) 
Median and 
IQR 
1.56 +/- 0.58 3.63 +/- 2.13 5.49 +/- 1.04  7.63 +/- 1.73 0.127 
0.8 
(0, 2.08) 
0.9 
(0, 3.2) 
3.2 
(1.1, 7.92) 
4.4 
(1.8, 11.1) 
ESR 
(mean+/- SE) 
Median and 
IQR 
7.5 +/- 1.38 9.78 +/- 2.52 19.44 +/- 2.60 30.33 +/- 
3.46 
0.000 
5 
(5, 9.25) 
7 
(5, 13) 
13.5 
(7, 25.25) 
32 
(12, 37) 
% RF 
positive  
0.5 0.67 0.58 0.55 0.881 
% ACPA 
positive  
0.5 0.56 0.42 0.55 0.690 
Number of 
joints with 
SH gr 1 
0 
(0, 0.5) 
0 
(0, 0.5) 
0 
(0, 8.5) 
0 
(0, 2) 
0.365 
(median and 
IQR) 
Number of 
joints with 
SH gr 2 
(median and 
IQR) 
0 
(0, 0) 
0 
(0, 0) 
0 
(0, 0) 
0 
(0, 0) 
0.836 
Number of 
joints with 
SH gr 3 
(median and 
IQR) 
1 
(0, 3.25) 
0 
(0, 3) 
2 
(0, 4.25) 
3 
(0, 5) 
0.639 
Number of 
joints with 
PD (median 
and IQR) 
0.5 
(0, 1) 
0 
(0, 1) 
1 
(0, 3) 
1 
(0, 4) 
0.051 
Number of 
joints with 
osteophytes 
(median and 
IQR) 
0 
(0, 5.75) 
6 
(0, 7) 
3.5 
(0, 8) 
4 
(0, 7) 
0.993 
Number of 
joints with 
erosions 
(median and 
IQR) 
3.5 
(1, 6.25) 
4 
(2,  4) 
7 
(2, 10) 
5 
(1, 11) 
0.341 
%  patients 
with PD 
0.5 0.33 0.63 0.67 0.257 
TJC (mean+/- 
SD) 
1 +/- 1.21 2.56 +/- 1.81 6.51+/- 4.98 19.48 +/- 
7.78 
0.000 
SJC (mean+/- 
SD) 
1.75 +/- 5.74 1.22 +/- 1.92 4.98 +/- 3.35 5.94 +/- 5.09 0.002 
GVAS 
(mean+/- SD) 
18.42 +/- 
24.74 
34.44 +/- 
18.73 
44.81 +/- 
25.44 
74.55  +/- 
17.74 
0.000 
Pain VAS 
(mean+/- SD) 
11.42 +/- 
13.45 
42 +/- 26.12 49 +/- 26.57 80 +/- 19.10 0.000 
 
 
 
 
Table 3: Comparison between S-IA patients with different levels of disease activity. 
 Disease 
activity 
S-IA (n 
=16) 
DAS-28<2.6 
 
 
S-IA (n = 5) 
DAS-28 = 
 2.6-3.2 
 
S-IA (n = 35) 
DAS 28 = 
3.2-5.1 
 
S-IA (n = 26) 
DAS-28> 5.1 
 
ANOVA/ 
Chi-squared 
test 
Mean age +/- 
SD 
46.41+/- 
12.86 
47 +/- 8.75 52.4 +/- 15.81 53.04 +/- 17.16 0.466 
Sex (% 
female) 
0.41 0.4  0.51 0.73 0.146 
Duration of 
the symptoms  
2.37 1.5 2.11 3.98 +/- 4.73 0.152 
hsCRP (mean 
+/- SE) 
Median and 
IQR 
1.69 +/- 
0.383 
2.86 +/- 1.88 4.5 +/-  1.11 15.48 +/- 4.43 0.004 
1.3 
(0.6, 2.6) 
0 
(0, 5) 
2.3 
(0.9, 4.9) 
6.8 
(3.55, 13.83) 
ESR 
(mean+/- SE) 
Median and 
IQR 
7.53 +/- 1.22 11.6 +/- 5.64 14.2 +/- 1.58 31.44 +/- 4.61 0.000 
5 
(4, 11) 
6 
(6, 8) 
11 
(7, 22) 
25 
(19, 35) 
% RF 
positive  
0.24 0 0.34 0.19 0.293 
% ACPA 
positive  
0.12 0.2 0.03 0.19 0.199 
Number of 
joints with 
SH gr 1 
(median and 
IQR) 
0 
(0, 0) 
0 
(0, 1) 
0 
(0, 2) 
0 
(0, 2) 
0.929 
Number of 
joints with 
SH gr 2 
(median and 
IQR) 
0 
(0, 0) 
0 
(0, 0) 
0 
(0, 0) 
0 
(0, 0) 
0.632 
Number of 
joints with 
SH gr 3 
(median and 
IQR) 
0 
(0, 0) 
0 
(0, 4) 
0 
(0, 3) 
2.5 
(0, 5.75) 
0.023 
Number of 
joints with 
PD (median 
and IQR) 
0 
(0, 0) 
0 
(0, 0) 
0 
(0, 0) 
1 
(0, 3) 
0.000 
Number of 
joints with 
osteophytes 
(median and 
IQR) 
2 
(0, 6) 
3 
(2, 5) 
3 
(1.5, 7) 
4 
(1, 6.75) 
0.695 
Number of 
joints with 
erosions 
(median and 
IQR) 
0 
(0, 0) 
0 
(0, 1) 
0 
(0, 0.5) 
0 
(0, 2) 
0.096 
%  patients 
with PD 
0.06 0 0.2 0.54 0.001 
TJC (mean+/- 
SD) 
0.29 +/- 0.59 1.8 +/- 0.837 7.37 +/- 6.10 18.19 +/- 8.43 0.000 
SJC (mean+/- 
SD) 
0.24 +/- 0.75 0  2.28 +/- 4.76 5.38 +/- 6.82 0.006 
GVAS 
(mean+/- SD) 
24.41 +/- 
22.35 
55 +/- 29.15 64 +/- 19.73 73.46 +/- 17.42 0.000 
Pain VAS 
(mean+/- SD) 
36.43 +/- 
32.75 
55 +/- 25.17 62.22  +/- 
21.57 
71.87 +/- 23.15 0.023 
 
 
 
 
 
Table 4: Comparison between RA and S-IA patients in clinical remission, with low, moderate or high 
disease activity based on the DAS 28 cut-offs.  
 
Disease 
activity 
RA vs. S-IA 
 (patients with 
DAS28<2.6) 
(p value) 
RA vs. S-IA 
(patients with 
DAS28=2.6-3.2) 
(p value) 
RA vs. S-IA 
(patients with 
DAS28 = 3.2-5.1) 
(p value) 
RA vs. S-IA 
(patients with 
DAS28> 5.1) 
(p value) 
Mean age  0.67 
(0.912) 
-0.67 
(0.92) 
5.77 
(0.102) 
4.32 
(0.317) 
Sex (% 
female) 
0.254 
(0.329) 
0.156 
(0.000) 
0.114 
(0.281) 
-0.03 
(0.999) 
Duration of 
the symptoms  
5.549 
(0.004) 
5.21 
(0.168) 
9.33 
(0.00) 
4.32 
(0.02) 
CRP  -0.13 
(0.847) 
0.773 
(0.814) 
0.98 
(0.53) 
-7.85 
(0.078) 
ESR  
 
-0.029 
(0.98) 
-1.822 
(0.738) 
5.24 
(0.13) 
-1.107 
(0.845) 
 RF positive  0.265 
(0.28) 
0.67 
(0.064) 
0.234 
(0.054) 
0.353 
(0.013) 
ACPA 
positive  
0.382 
(0.065) 
0.356 
(0.469) 
0.395 
(0.000) 
0.353 
(0.013) 
Number of 
joints with 
SH gr 1  
-0.09 
(0.90) 
1.578 
(0.618) 
2.34 
(0.02) 
1.26 
(0.267) 
Number of 
joints with 
SH gr 2  
0.82 
(0.268) 
1.11 
(0.478) 
0.773 
(0.125) 
0.52 
(0.238) 
Number of 
joints with 
SH gr 3  
0.941 
(0.313) 
0.09 
(0.944) 
1.08 
(0.104) 
-0.456 
(0.628) 
Number of 
joints with 
PD  
0.608 
(0.005) 
0.33 
(0.169) 
1.92 
(0.01) 
0.682 
(0.516) 
Number of 
joints with 
osteophytes  
0.686 
(0.733) 
1.47 
(0.445) 
0.226 
(0.826) 
-0.446 
(0.734) 
Number of 
joints with 
erosions  
4.63 
(0.003) 
3.49 
(0.047) 
5.96 
(0.000) 
5.43 
(0.000) 
Number of 
patients with 
PD 
0.44 
(0.02) 
0.33 
(0.437) 
0.43 
(0.00) 
0.128 
(0.46) 
TJC  0.706 
(0.046) 
0.756 
(0.401) 
-0.86 
(0.475) 
1.29 
(0.544) 
SJC  1.515 1.22 1.01 0.555 
(0.290) (0.189) (0.252) (0.72) 
GVAS  -6.00 
(0.502) 
-20.56 
(0.132) 
-19.19 
(0.000) 
1.08 
(0.815) 
Pain VAS  -25  
(0.09) 
-13.00 
(0.476) 
-13.22 
(0.08) 
8.125 
(0.2707) 
 
Table 5: Marginal effects of different variables on the number of joints with PD signal in patients with 
other arthropathies vs. S-IA vs. RA 
 
RA 
status (n=108) 
0 0 1 
Suspicion of IA (S-IA) 
status (n=92) 
0 1 0 
RF 2.76 
(2.32, 3.21) 
0.11 
(-0.25, 0.46) 
-0.09  
(-0.23,  0.06) 
CCP  -0.75 
(-1.07, -0.42) 
0.01061559 
(-0.35,  0.37) 
0.65  
(0.50, 0.80) 
MTX - - 0.01  
(-0.12,  0.13) 
Etanercept - - 0.01  
(-0.12,  0.13) 
Rituximab - - 0.62  
(0.45, 0.79) 
Tocilizumab - - -1.81  
(-1.90, -1.72) 
Adalimumab - - 0.79  
(0.58, 1.01) 
hsCRP (>5 mg/l) 0.0278 
(0.0277, 0.0279) 
0.004856  
(0.004850, 0.004862) 
0.0546  
(0.0544, 0.0547) 
ESR 0.01551 
(0.01548, 0.01555) 
0.01880  
(0.01871, 0.01889) 
0.007728  
(0.007725, 0.007731) 
TJC -0.00915 
(-0.00917, -0.00914) 
0.02020  
(0.02010, 0.02030) 
-0.0018359  
(-0.0018360, -0.0018357) 
SJC 0.100 
(0.099, 0.102) 
0.086  
(0.0841, 0.0879) 
0.214  
(0.212, 0.216) 
GVAS 0.004594 
(0.004590, 0.004597) 
-0.01021  
(-0.01024, -0.01019) 
-0.005323  
(-0.005324, -0.005321) 
 
 
 
 
  
 
 
 
 
